UBS Group reaffirmed their neutral rating on shares of GlaxoSmithKline (LON:GSK) in a report released on Thursday morning, ThisIsMoney.Co.Uk reports.
Several other equities analysts have also recently issued reports on GSK. Liberum Capital reaffirmed a hold rating on shares of Daily Mail and General Trust P L C in a research note on Tuesday, July 2nd. Credit Suisse Group initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, May 20th. They issued a neutral rating and a $336.00 price objective on the stock. Jefferies Financial Group reaffirmed a buy rating and issued a C$15.00 price objective on shares of Aphria in a research note on Friday, May 24th. Shore Capital reaffirmed a house stock rating on shares of TLOU Energy in a research note on Wednesday. Finally, Morgan Stanley initiated coverage on shares of in a research note on Monday, June 17th. They issued an equal weight rating and a GBX 215 ($2.81) price objective on the stock. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of GBX 1,532.32 ($20.02).
Shares of GSK opened at GBX 1,623.80 ($21.22) on Thursday. The stock has a 50 day simple moving average of GBX 1,584.74. The firm has a market cap of $81.00 billion and a PE ratio of 20.69. The company has a debt-to-equity ratio of 942.07, a current ratio of 0.72 and a quick ratio of 0.45. GlaxoSmithKline has a 12-month low of GBX 1,408.80 ($18.41) and a 12-month high of GBX 1,651 ($21.57).
The company also recently announced a dividend, which was paid on Thursday, July 11th. Shareholders of record on Thursday, May 16th were issued a GBX 19 ($0.25) dividend. This represents a dividend yield of 1.22%. The ex-dividend date of this dividend was Thursday, May 16th. GlaxoSmithKline’s payout ratio is 0.97%.
In other news, insider Manvinder Singh Banga bought 458 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was bought at an average cost of GBX 1,568 ($20.49) per share, for a total transaction of £7,181.44 ($9,383.82). Over the last quarter, insiders acquired 482 shares of company stock valued at $755,935.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Article: Treasury Bonds
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.